Knight Aaron D, Kacker Sandeep
Pharmacology and Therapeutics, Medical University of the Americas, Devens, USA.
Cureus. 2023 Jan 2;15(1):e33265. doi: 10.7759/cureus.33265. eCollection 2023 Jan.
This study was conducted to test the hypothesis that platelet-rich plasma (PRP) therapy in chronic respiratory disease patients will cause lung regeneration, thereby slowing the progression of the disease. We performed a search to obtain pertinent articles on the following electronic databases: Google Scholar, PubMed, NCBI, Medscape, and clinicaltrials.gov. Keywords used during in search included "Platelet Rich Plasma" AND "Chronic Respiratory Disease" AND/OR "Chronic Obstructive Pulmonary Disease". A total of 15 articles were chosen for this paper, published from 2011 to 2021, and included case series, lab studies, animal studies, cohort studies, and clinical trials. All statistical data were considered significant if the p-value was less than 5%, or 0.05. Our findings confirmed that PRP therapy successfully caused anti-inflammatory effects and acceleration of tissue regeneration, resulting in improved lung function. This, in turn, slowed the progression of the disease and led to an improved quality of life. Not all chronic respiratory disease patients present in the same manner, but the connecting link is the damaged tissue of the lungs, causing issues with the functionality of the lungs. By adjunctively treating patients with PRP, the high concentration of platelets and their secreted growth factors can help induce an acceleration of healing and regeneration of pulmonary tissue. This, in turn, can slow the progression of the disease, which could lower the overall mortality rate in chronic respiratory disease patients. More studies should be conducted on this topic, specifically large, double-blinded, randomized human trials with controls, to further assess the efficacy and beneficial effects of PRP treatment on the lungs.
慢性呼吸道疾病患者接受富血小板血浆（PRP）治疗可促进肺组织再生，从而减缓疾病进展。我们在以下电子数据库中进行检索以获取相关文章：谷歌学术、PubMed、NCBI、Medscape和clinicaltrials.gov。检索时使用的关键词包括“富血小板血浆”以及“慢性呼吸道疾病”和/或“慢性阻塞性肺疾病”。本文共选取了15篇文章，发表时间为2011年至2021年，包括病例系列、实验室研究、动物研究、队列研究和临床试验。如果p值小于5%，即0.05，则所有统计数据均被视为具有显著性。我们的研究结果证实，PRP治疗成功产生了抗炎作用并加速了组织再生，从而改善了肺功能。这进而减缓了疾病进展，提高了生活质量。并非所有慢性呼吸道疾病患者的表现都相同，但共同之处在于肺部组织受损，导致肺功能出现问题。通过用PRP辅助治疗患者，高浓度的血小板及其分泌的生长因子可有助于促进肺组织的愈合和再生。这进而可以减缓疾病进展，降低慢性呼吸道疾病患者的总体死亡率。关于这个主题应开展更多研究，特别是大规模、双盲、有对照的随机人体试验，以进一步评估PRP治疗对肺部的疗效和有益效果。
